This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
by Zacks Equity Research
Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.
RHHBYNegative Net Change CRMDPositive Net Change PCSAPositive Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals
INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset
by Zacks Equity Research
Insmed sinks nearly 20% after Brinsupri failed a phase IIb sinus study, while the company adds a new monoclonal antibody asset to expand its pipeline.
INSMPositive Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechs medical
5 Biotech Stocks to Watch for Potential Upside
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.
ARQTNegative Net Change FOLDPositive Net Change PCRXNegative Net Change ANIPNegative Net Change TNGXPositive Net Change
biotechnology biotechs medical pharmaceuticals
CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?
by Kanishka Das
CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.
PFEPositive Net Change PBYINegative Net Change CRMDPositive Net Change
biotechs
GSK's Exdensur Gets FDA Nod for Severe Asthma Treatment
by Zacks Equity Research
GSK secures FDA approval for Exdensur, the first twice-yearly biologic for treating severe asthma with an eosinophilic phenotype.
GSKPositive Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechs
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
by Sundeep Ganoria
PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change SMMTPositive Net Change
biotechs medical pharmaceuticals vaccines
RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
by Zacks Equity Research
Rezolute shares collapse 79% so far in December after a phase III hyperinsulinism study of its only pipeline candidate miss primary and key secondary endpoints.
ANIPNegative Net Change CRMDPositive Net Change RZLTNegative Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer
by Zacks Equity Research
AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.
AZNNegative Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechs
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
by Zacks Equity Research
Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its primary endpoint.
SNYNegative Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechs medical pharmaceuticals
FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock?
by Zacks Equity Research
Amicus hits a 52-week high after an 87.6% six-month surge, driven by strong Galafold sales and rising uptake of Pombiliti + Opfolda.
SNYNegative Net Change TEVANegative Net Change FOLDPositive Net Change
biotechs
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
by Zacks Equity Research
Kyverna Therapeutics shares jump 23% after a registrational phase II study of miv-cel meets primary and all secondary efficacy goals for treating stiff person syndrome.
ANIPNegative Net Change CRMDPositive Net Change CSTLNegative Net Change KYTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike
by Zacks Equity Research
CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.
MRNAPositive Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals vaccines
How AbbVie's Pipeline Is Lining Up Key Product Launches
by Sundeep Ganoria
ABBV is lining up multiple late-stage launches, from Rinvoq label expansions to Parkinson???s and oncology assets nearing FDA decisions.
JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal
by Zacks Equity Research
Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.
GSKPositive Net Change GILDNegative Net Change FOLDPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer
by Zacks Equity Research
JNJ secures FDA approval to expand Akeega into earlier-stage prostate cancer, backed by strong phase III data and a first-of-its-kind precision combo.
GSKPositive Net Change JNJPositive Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechs medical
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
by Zacks Equity Research
NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU
by Zacks Equity Research
GSK gets CHMP backing for Nucala in COPD and depemokimab in asthma, setting up possible Europe approvals in 2026 for IL-5 therapies.
GSKPositive Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechs medical
RCUS Stock Down on Decision to Discontinue GILD Partnered Study
by Zacks Equity Research
Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down.
GILDNegative Net Change FOLDPositive Net Change CRMDPositive Net Change RCUSNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.
BMYNegative Net Change PFEPositive Net Change MRKPositive Net Change
biotechs medical pharmaceuticals
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win
by Zacks Equity Research
LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
by Zacks Equity Research
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
RHHBYNegative Net Change BMYNegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Kymera's Eczema Drug Gets Fast Track Designation in the United States
by Zacks Equity Research
KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.
SNYNegative Net Change GILDNegative Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea
by Zacks Equity Research
GSK wins FDA approval for Blujepa, a new oral antibiotic treatment option for uncomplicated urogenital gonorrhea.
GSKPositive Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechs
Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis
by Sundeep Ganoria
AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.
JNJPositive Net Change AMGNPositive Net Change ARGXNegative Net Change
biotechs medical pharmaceuticals